CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

By François Ghiringhelli, N. Larmonier, E. Schmitt, Arnaud Parcellier, Dominique Cathelin, C. Garrido, B. Chauffert, E. Solary, B. Bonnotte, F. Martin. European Journal of Immunology, 2004

998 citations recorded by the source corpus.

Subfields: Immunology

View Paper: https://www.semanticscholar.org/paper/008000d9005c91351aa6822201ecdaed440db5d1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Guido Kroemer
2. L. Zitvogel
3. L. Galluzzi
4. D. Munn
5. A. Mellor
6. Oliver Kepp
7. George Coukos
8. A. Buqué

Citations in the corpus

• T Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis (2012, background): “Cyclophosphamide has been shown to preferentially deplete CD4þCD25þ Tregs in rats, and in one study (54), only a single”
• Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients (2007, background): “In tumor-bearing animals, Treg can also curtail antitumor immune responses [3, 4].”
• Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. (2015, background): “…therapeutic effects Gershan et al., 2015) transplantable rat CRC depletes TREG cells enables immunotherapy to ediate complete tumor regression Ghiringhelli et al., 2004) Dacarbazine melanoma induces lymphopenia important for the clinical management of melanoma Mignot et al., 2014) Docetaxel…”
• Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy (2016, positive): “Because Cyc can suppress Treg cells (Ghiringhelli et al., 2004; Lutsiak et al., 2005), Oxa-Cyc might promote antitumor responses by acting on Treg cells directly.”
• FOXP3+ regulatory T cells in the human immune system (2010, background): “Small molecules, such as cyclophosphamide, that deplete T Reg cells can also enhance tumour-specific immunit”
• 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. (2010, background): “Cyclophosphamide had a T-dependent antitumor effect that was annihilated by an adoptive transfer of Treg cells (25, 30).”
• Metronomic chemotherapy: new rationale for new directions (2010, background): “Several studies performed in tumor-bearing animals have shown that low-dose cyclophosphamide can increase anti-tumor immune response by decreasing numbers and inhibiting the suppressive functions of T REG cells but also by increasing both lymphocyte proliferation and memory T cells”
• Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. (2007, background): “Certain chemotherapeutic drugs such as cyclophosphamide have been reported to partially reduce the number and/or function of Tregs (30, 31).”